Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesity [0.03%]
面对面生活方式干预与数字化增强生活方式干预治疗超重和肥胖成人疗效的meta分析
Diego Anazco,Maria A Espinosa,Lizeth Cifuentes et al.
Diego Anazco et al.
Background: Lifestyle interventions (LIs) are the cornerstone for obesity management. The Mayo Clinic Diet (MCD) offers two approaches for LIs: the In-Person LI (IPLI) and the Digital Enhanced LI (DELI). The IPLI includes...
Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review [0.03%]
南亚人代谢功能异常相关性肝脂肪变病的诊断与治疗——临床综述
Prajith Raj Ramesh,Priya Krishnan,Samyuktha Prabu et al.
Prajith Raj Ramesh et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed as nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of obesity and metabolic syndrome. It is mainly caused...
Varalakshmi Niranjan,Jennifer Ozimek
Varalakshmi Niranjan
Background: South Asians are defined as those indigenous to the Indian subcontinent - India, Pakistan, Sri Lanka, Nepal, Maldives, Bhutan, and Bangladesh. This ethnic group is a unique population with increased prevalence...
Case Reports
Obesity pillars. 2024 Oct 1:12:100137. DOI:10.1016/j.obpill.2024.100137 2024
Obesity in patients with craniopharyngioma in the South Asian region - A distinct phenotype [0.03%]
南亚颅咽管瘤患者的肥胖现象-一种独特的表型特征
Sreevatsa Tatachar,Remya Rajan,Asha Hesaraghatta Shyamsunder et al.
Sreevatsa Tatachar et al.
Background: Craniopharyngiomas are rare benign tumors located in the sellar and suprasellar region, with an incidence of 0.5-2 cases per million as reported in Western studies. Post-treatment, including surgery and/or rad...
Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product [0.03%]
GLP-1受体激动剂与代餐联合治疗肥胖7例回顾分析
Catherine Bacus,Terri-Lynne South,Sonia Raudszus et al.
Catherine Bacus et al.
Background: The use of meal replacement products (MRPs) to obtain a caloric deficit while maintaining micro- and macronutrient requirements, has a long tradition in obesity medicine. Limitations include low compliance, va...
Effects of native vitamin D supplementation on vitamin D status and body composition after sleeve gastrectomy: A retrospective study in Japanese patients [0.03%]
日本患者行袖状胃切除术后补充国产维生素D对体内维生素D状况及机体成分的影响：一项回顾性研究
Takashi Yamaguchi,Saori Kawakubo,Kazue Yamaura et al.
Takashi Yamaguchi et al.
Introduction: The effect of vitamin D status after bariatric surgery on postoperative skeletal muscle condition has not been adequately studied. Methods: ...
Reliable prediction of childhood obesity using only routinely collected EHRs may be possible [0.03%]
仅基于常规收集的EHR可能可以可靠地预测儿童肥胖症
Mehak Gupta,Daniel Eckrich,H Timothy Bunnell et al.
Mehak Gupta et al.
Background: Early identification of children at high risk of obesity can provide clinicians with the information needed to provide targeted lifestyle counseling to high-risk children at a critical time to change the disea...
Adoption of telemedicine for obesity treatment during the COVID-19 pandemic achieved comparable outcomes to in-person visits [0.03%]
新冠肺炎疫情期间肥胖症的远程医疗应用效果不输当面就诊
Andrés R Latorre-Rodríguez,Raj H Shah,Seema Munir et al.
Andrés R Latorre-Rodríguez et al.
Background: During the COVID-19 pandemic, weight loss programs rapidly transitioned to a virtual model, replacing in-person clinic visits. We sought to compare the observed weight loss and adherence to treatment between p...
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks [0.03%]
GLP-1受体激动剂治疗肥胖：减重效果、耐受性、不良反应及风险
Wissam Ghusn,Maria D Hurtado
Wissam Ghusn
Background: This review investigates the side effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for their efficacy in promoting weight loss a...
Corrigendum to "Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings" [Obes. Pillars, Volume 11, September 2024, 100112] [0.03%]
关于“临床美国环境下内镜袖状胃成形术联合抗肥胖药物使用的结果”的勘误声明[Obes. Pillars，第11卷，2024年9月，100112]
Khushboo Gala,Wissam Ghusn,Vitor Brunaldi et al.
Khushboo Gala et al.
[This corrects the article DOI: 10.1016/j.obpill.2024.100112.]. © 2024 The Author(s).
Published Erratum
Obesity pillars. 2024 Jun 29:11:100116. DOI:10.1016/j.obpill.2024.100116 2024